Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Arcturus Therapeutics Holdings Inc (ARCT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arcturus Therapeutics Holdings Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.55 +0.38    +1.45%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
26.55
0.00
0.00%
17:05:33 - Real-time Data
  • Volume: 259,943
  • Bid/Ask: 25.85 / 28.81
  • Day's Range: 25.84 - 26.86
Type:  Equity
Market:  United States
Arcturus Therapeutics Holdings Inc 26.55 +0.38 +1.45%

Arcturus Therapeutics Holdings Inc Company Profile

 
Get an in-depth profile of Arcturus Therapeutics Holdings Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

170

Equity Type

ORD

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Contact Information

Address 10628 Science Center Drive Suite 250
San Diego, 92121
United States
Phone 858 900 2660
Fax -

Top Executives

Name Age Since Title
Andrew H. Sassine 57 2018 CFO & Director
Peter C. Farrell 79 2018 Independent Chairman of the Board
Karah Herdman Parschauer 43 2019 Director
Joseph E. Payne 49 2013 Founder, President, CEO & Director
Peter A. Patriarca - 2020 Member of the Vaccine Platform Scientific Advisory Board
Robert T. Schooley - 2020 Member of the Vaccine Platform Scientific Advisory Board
Eng Eong Ooi - 2020 Member of the Vaccine Platform Scientific Advisory Board
Jeffrey William Colyer - 2020 Member of the Vaccine Platform Scientific Advisory Board
Frederick G. Hayden - 2020 Member of the Vaccine Platform Scientific Advisory Board
Jonathan F. Smith - 2020 Member of the Vaccine Platform Scientific Advisory Board
Jing L. Marantz 57 2021 Independent Director
John H. Markels 56 2022 Director
Magda Marquet 64 2018 Independent Director
Michael R. Hodges - 2014 Member of Scientific Advisory Board
Drew Weissman - 2015 Member of Scientific Advisory Board
James F. Barlow 64 2018 Independent Director
Steven George Hughes 55 2022 Strategic Clinical Advisor & Member of Scientific Advisory Board
Edward W. Holmes 82 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARCT Comments

Write your thoughts about Arcturus Therapeutics Holdings Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Babar Abbasi
Babar Abbasi Dec 28, 2020 21:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what happen to this
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email